Bristol Myers Squibb Signs Protein Degradation and Cell Therapy Technology Deals
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 10 (Table of Contents)
Published: 8 Oct-2022
DOI: 10.3833/pdr.v2022.i10.2731 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Bristol Myers Squibb (BMS) has entered into two separate research collaboration and license agreements with SyntheX and Autolus Therapeutics to expand its protein degradation and cell therapy portfolios...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS